309 related articles for article (PubMed ID: 30037819)
1. Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.
Ishida CT; Zhang Y; Bianchetti E; Shu C; Nguyen TTT; Kleiner G; Sanchez-Quintero MJ; Quinzii CM; Westhoff MA; Karpel-Massler G; Prabhu VV; Allen JE; Siegelin MD
Clin Cancer Res; 2018 Nov; 24(21):5392-5406. PubMed ID: 30037819
[No Abstract] [Full Text] [Related]
2. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS
Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985
[TBL] [Abstract][Full Text] [Related]
3. Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma.
Zhang Y; Ishida CT; Ishida W; Lo SL; Zhao J; Shu C; Bianchetti E; Kleiner G; Sanchez-Quintero MJ; Quinzii CM; Westhoff MA; Karpel-Massler G; Canoll P; Siegelin MD
Clin Cancer Res; 2018 Aug; 24(16):3941-3954. PubMed ID: 29764852
[No Abstract] [Full Text] [Related]
4. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.
Tateishi K; Iafrate AJ; Ho Q; Curry WT; Batchelor TT; Flaherty KT; Onozato ML; Lelic N; Sundaram S; Cahill DP; Chi AS; Wakimoto H
Clin Cancer Res; 2016 Sep; 22(17):4452-65. PubMed ID: 27076630
[TBL] [Abstract][Full Text] [Related]
5. MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma.
Zhang Y; Nguyen TTT; Shang E; Mela A; Humala N; Mahajan A; Zhao J; Shu C; Torrini C; Sanchez-Quintero MJ; Kleiner G; Bianchetti E; Westhoff MA; Quinzii CM; Karpel-Massler G; Bruce JN; Canoll P; Siegelin MD
Cancer Res; 2020 Jan; 80(1):30-43. PubMed ID: 31694905
[TBL] [Abstract][Full Text] [Related]
6. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
7. Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma.
Nguyen TTT; Shang E; Schiffgens S; Torrini C; Shu C; Akman HO; Prabhu VV; Allen JE; Westhoff MA; Karpel-Massler G; Siegelin MD
Clin Cancer Res; 2022 May; 28(9):1881-1895. PubMed ID: 35417530
[TBL] [Abstract][Full Text] [Related]
8. A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma.
Laks DR; Oses-Prieto JA; Alvarado AG; Nakashima J; Chand S; Azzam DB; Gholkar AA; Sperry J; Ludwig K; Condro MC; Nazarian S; Cardenas A; Shih MYS; Damoiseaux R; France B; Orozco N; Visnyei K; Crisman TJ; Gao F; Torres JZ; Coppola G; Burlingame AL; Kornblum HI
Neuro Oncol; 2018 May; 20(6):764-775. PubMed ID: 29136244
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.
Wang G; Fu XL; Wang JJ; Guan R; Sun Y; Tony To SS
J Cell Physiol; 2019 May; 234(5):5888-5903. PubMed ID: 29336479
[TBL] [Abstract][Full Text] [Related]
10. Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.
Olmez I; Brenneman B; Xiao A; Serbulea V; Benamar M; Zhang Y; Manigat L; Abbas T; Lee J; Nakano I; Godlewski J; Bronisz A; Abounader R; Leitinger N; Purow B
Clin Cancer Res; 2017 Nov; 23(22):6958-6968. PubMed ID: 28814434
[No Abstract] [Full Text] [Related]
11. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
Ma Y; Tang N; Thompson RC; Mobley BC; Clark SW; Sarkaria JN; Wang J
Clin Cancer Res; 2016 Apr; 22(7):1767-76. PubMed ID: 26561558
[TBL] [Abstract][Full Text] [Related]
12. Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models.
Netland IA; Førde HE; Sleire L; Leiss L; Rahman MA; Skeie BS; Gjerde CH; Enger PØ; Goplen D
BMC Cancer; 2016 Aug; 16():657. PubMed ID: 27542970
[TBL] [Abstract][Full Text] [Related]
13. Adaptive mitochondrial reprogramming and resistance to PI3K therapy.
Ghosh JC; Siegelin MD; Vaira V; Faversani A; Tavecchio M; Chae YC; Lisanti S; Rampini P; Giroda M; Caino MC; Seo JH; Kossenkov AV; Michalek RD; Schultz DC; Bosari S; Languino LR; Altieri DC
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25650317
[TBL] [Abstract][Full Text] [Related]
14. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
15. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
16. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.
Nii T; Prabhu VV; Ruvolo V; Madhukar N; Zhao R; Mu H; Heese L; Nishida Y; Kojima K; Garnett MJ; McDermott U; Benes CH; Charter N; Deacon S; Elemento O; Allen JE; Oster W; Stogniew M; Ishizawa J; Andreeff M
Leukemia; 2019 Dec; 33(12):2805-2816. PubMed ID: 31127149
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin.
Kim EH; Lee JH; Oh Y; Koh I; Shim JK; Park J; Choi J; Yun M; Jeon JY; Huh YM; Chang JH; Kim SH; Kim KS; Cheong JH; Kim P; Kang SG
Neuro Oncol; 2017 Feb; 19(2):197-207. PubMed ID: 27571886
[TBL] [Abstract][Full Text] [Related]
18. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
[TBL] [Abstract][Full Text] [Related]
19. A Novel Platinum-Maurocalcine Conjugate Induces Apoptosis of Human Glioblastoma Cells by Acting through the ROS-ERK/AKT-p53 Pathway.
Aroui S; Dardevet L; Ben Ajmia W; de Boisvilliers M; Perrin F; Laajimi A; Boumendjel A; Kenani A; Muller JM; De Waard M
Mol Pharm; 2015 Dec; 12(12):4336-48. PubMed ID: 26465677
[TBL] [Abstract][Full Text] [Related]
20. Regulation of death induction and chemosensitizing action of 3-bromopyruvate in myeloid leukemia cells: energy depletion, oxidative stress, and protein kinase activity modulation.
Calviño E; Estañ MC; Sánchez-Martín C; Brea R; de Blas E; Boyano-Adánez Mdel C; Rial E; Aller P
J Pharmacol Exp Ther; 2014 Feb; 348(2):324-35. PubMed ID: 24307199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
